43
Participants
Start Date
July 21, 2021
Primary Completion Date
April 1, 2023
Study Completion Date
April 1, 2023
Poly-ICLC (Hiltonol®) or Placebo
The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
Poly-ICLC (Hiltonol®) or Placebo
The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
Health Research Innovation Centre, Calgary
Lead Sponsor
University of Calgary
OTHER
Oncovir, Inc.
INDUSTRY